Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Viking Therapeutics Inc (VKTX) USD0.00001

Sell:$6.60 Buy:$6.92 Change: $0.41 (5.78%)
NASDAQ:0.52%
Market closed |  Prices as at close on 2 July 2020 | Switch to live prices |
Sell:$6.60
Buy:$6.92
Change: $0.41 (5.78%)
Market closed |  Prices as at close on 2 July 2020 | Switch to live prices |
Sell:$6.60
Buy:$6.92
Change: $0.41 (5.78%)
Market closed |  Prices as at close on 2 July 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company's clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Contact details

Address:
12340 El Camino Real Ste 250
SAN DIEGO
92130-3093
United States
Telephone:
+1 (858) 7044660
Website:
www.vikingtherapeutics.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VKTX
ISIN:
US92686J1060
Market cap:
$514.71 million
Shares in issue:
72.60 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Lawson Macartney
    Independent Chairman of the Board
  • Brian Lian
    President, Chief Executive Officer, Director
  • Greg Zante
    Senior Vice President - Finance, IR Contact Officer
  • Michael Morneau
    Vice President - Finance and Administration

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.